Previous Close | 217.30 |
Open | 215.83 |
Bid | 215.00 x 800 |
Ask | 218.20 x 800 |
Day's Range | 215.06 - 219.07 |
52 Week Range | 187.16 - 351.86 |
Volume | |
Avg. Volume | 1,069,020 |
Market Cap | 31.664B |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | 15.53 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for BIIB
Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.
Millions of Americans are eagerly waiting to find out how much their Social Security cost-of-living adjustment (COLA) will be for 2023. One big reason why that's the case is that Social Security's COLA calculation doesn't include Medicare Part B premiums. You might wonder how Medicare Part B premiums could possibly decline.
The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.